BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials

Journal of Cellular Biochemistry

Volumn 77, Issue SUPPL. 34, 2000, Pages 13-18

  Levy Lahad, Ephrat ^a,c   Krieger, Michal ^a   Gottfeld, Orit ^a   Renbaum, Paul ^a   Klein, Gaya ^a   Eisenberg, Shlomit ^a   Lahad, Amnon ^b   Kaufman, Bella ^c   Catane, Raphael ^c  

^a HEBREW UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Ashkenazi Jews; Breast cancer; Cancer genetics; Israel; Ovarian cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ANTINEOPLASTIC AGENT; TAMOXIFEN; TRANSCRIPTION FACTOR; TUMOR PROTEIN;

BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; BREAST TUMOR; CLINICAL TRIAL; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; JEW; MUTATION; OVARY TUMOR;

ANTICARCINOGENIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; JEWS; MUTATION; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TAMOXIFEN; TRANSCRIPTION FACTORS;

EID: 0033644560     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(2000)77:34+<13::AID-JCB4>3.0.CO;2-F     Document Type: Review

References (15)

1. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T. 1997. The Founder Mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505-514.
2. Ben David Y, Hirsch Y, Anderman S, Anteby S, Atad J, Beck D, Beller V, The Israel Ovarian Cancer Study Group. The effect of BRCA1 185delAG mutation on length of survival in ovarian tumors. 29th Annual Meeting of the Society of Gynecologic Oncology. Orlando, FL, Feb. 1998.
3. Breast Cancer Linkage Consortium. 1997. Pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349:1505-1510.
4. Brody LC, Biesecker BB. 1998. Breast cancer susceptibility genes. BRCA1 and BRCA2. Medicine (Baltimore) 77:208-226.
5. Claus EB, Risch N, Thompson WD. 1991. Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 48:232-242.
6. Easton DF, Ford D, Bishop DT, and the Breast Cancer Linkage Consortium. 1995. Breast and ovarian cancer incidence in BRCA1 Mutation carriers. Am J Hum Genet 56:265-271.
7. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronnin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
8. Fitzgerald M, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein D, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. 1996. N Engl J Med 334:143-149.
9. Fodor FH, Ainsley W, Bleiweiss IJ, McCurdy LD, Wlash MM, Tartter PI, Brower ST, Eng C. 1998. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish Breast Cancer Patients. Am J Hum Genet 63:45-51.
10. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, and the Breast Cancer Linkage Consortium. 1994. Risks of cancer in BRCAl-mutation carriers Lancet 343:692-695.
11. Hong WK, Sporn MB. 1997. Recent advances in chemoprevention of cancer. Science 278:1073-1077.
12. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinisky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D. 1997a. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60:1059-1067.
13. Levy-Lahad E, Gershoni-Baruch R, Sagi M., Orr-Urtreger A, Ben-Yehuda A, Dagan E, Bar-Sade R, Lahad A, Halle D, Peretz T, Friedman E. 1997b. Directly derived penetrance estimates for the founder BRCA1/BRCA2 mutations in Jews: the Israeli consortium on hereditary breast cancer. Am J Hum Genet 61S:A72.
14. Modan B, Gak E, Bar Sade-Baruchim R, Hirsh-Yechezkel G, Theodur L, Lubin F, Ben-Baruch G, Beller U, Fishman A, Dgani R, Menczer J, PapaM, Friedman E. 1996. High frequency of BRCA1 185delAG mutation in ovarian cancer in Israel. JAMA 276:1823-1825.
15. Motulsky AG. 1995. Jewish diseases and origins. Nature Genet 9:99-101.